ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
ADK-VR2 是一种源自未经治疗的 SDC4-ROS1 融合阳性原发性克唑替尼耐药 NSCLC 患者的细胞系：一种用于 ROS1 重排 NSCLC 新药开发的新型临床前模型
期刊:Translational Lung Cancer Research
影响因子:4
doi:10.21037/tlcr-22-163
Francesca Ruzzi #, Stefania Angelicola #, Lorena Landuzzi #, Elena Nironi, Maria Sofia Semprini, Laura Scalambra, Annalisa Altimari, Elisa Gruppioni, Michelangelo Fiorentino, Francesca Giunchi, Manuela Ferracin, Annalisa Astolfi, Valentina Indio, Andrea Ardizzoni, Francesco Gelsomino, Patrizia Nanni
